Navigation Links
Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
Date:11/1/2007

ADELAIDE, Australia, Nov. 1 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, announced today that the initial results of treating patients with Retina Regeneration Therapy (Ellex 2RT(TM)) will be presented by Peter Hamilton MD, FRCOph at the annual meeting of the American Academy of Ophthalmology, which takes place November 10-13, in New Orleans. Dr. Hamilton conducted the first patient treatments recently in London under the direction of Professor John Marshall, Ph.D., FRCPath. Professor Marshall, an Ellex board director, is currently Frost Professor of Ophthalmology at the Rayne Institute and Head of the Academic Department of Ophthalmology at King's College, University of London.

Ellex 2RT is a new non-thermal laser treatment that relies on nanosecond pulses of laser energy to stimulate the retinal pigment epithelium (RPE) to preserve vision. Laboratory research conducted under Professor Marshall over the past few years has demonstrated that the Ellex 2RT method causes the RPE to migrate and release matrix metalloproteinase (MMP's), which are the enzymes that clean up Bruch's membrane. Further laboratory experiments to measure the ability of Bruch's membrane to transport water and chemicals have shown the entire transport mechanism of the retina has been rejuvenated. Dr. Hamilton treated the initial series of patients in London following two years of laboratory research funded by Ellex and conducted under the direction of Professor Marshall at St. Thomas' Hospital in London, UK and Royal Adelaide Hospital in Adelaide, Australia.

"Dr. Hamilton's presentation of Ellex 2RT patient data at the AAO marks a milestone for Ellex and Professor Marshall's collaborative research program," commented Peter Falzon, Ellex CEO. "We are pleased to be working with Professor Marshall and Dr. Hamilton, long-time leaders in the field of ophthalmology, to advance the sc
'/>"/>

SOURCE Ellex Medical Lasers Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...OWN, W.Va., Nov. 21 New...ng whether a smokeless, spitless tobacco product a...rchers have found that RJ Reynolds, Camel Snus - t...ction - contains surprisingly high levels of nicot... than most other snuff products," said Bruce Adkin...
(Date:11/21/2008)...A, S.C., Nov. 21 U.S. N...for Quality Assurance (NCQA) ranked BlueChoice(R) ...merica,s Best Health Plans(TM), published in U.S. ..., The respected annual ranking ranks the nation,...ber satisfaction and NCQA accreditation scores. NC...
(Date:11/21/2008)...E, N.J., Nov. 21 Barr Ph... that its shareholders overwhelmingly approved the...sition of Barr by Teva Pharmaceuticals Industries ...demonstrated the overwhelming support of the trans...wney, Barr,s Chairman and CEO. "We are pleased wit...
(Date:11/21/2008)...0 B.C., a new and deadly diseaseits cause remains ...state was teeming with citizens, soldiers and refu...rta. As streets filled with corpses, social order ... returned twice and Athens lost a third of its pop... marked the beginning of the end of the Golden Age...
Breaking Medicine News(10 mins):Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...therapeutic regimens are effective in suppressing ...nged treatment may be complicated by development o...spite // continued concerns over the safety of int... in clinical practice interrupt therapy for reason...
...te in vitro fertilization (IVF) baby of a single p...tions about the newborn's legal status and the sin... whose childless marriage had ended in divorce yea...ountry's first single father whose son was born th...
...obe University of Australia have found a new combi...he parasite responsible for causing malaria. They ...or treatment // helps in killing P. falciparum whi...hloroquine is a largely used drug in the treatment...
...most common breathing problems encountered by many...s been a considerable increase in the incidence of...as been estimated that nearly 196,000 children are...ry year with asthma attacks. A considerable amount...
Other Medicine News:Health News:A first for India - IVF baby born of surrogacy 2Health News:Improved parent-physician communication to prevent hospitalizations for childhood asthma 2
(Date:11/20/2008)..., Switzerland, November 20 /PRNewswire-FirstCall/ ...ti-infective Drugs Advisory Committee of the,U.S....o 2 against the,approval of intravenous iclaprim,...reatment of patients with complicated skin and ski...caused by methicillin-resistant Staphylococcus,au...
(Date:11/20/2008)... Calif., Nov. 20 Bionovo...ll present results from the Phase 1B,clinical tri...tatic breast,cancer, BZL101, at the Society for I...nce in Atlanta, Georgia. The Company,s oral prese...d will be presented as a part of the Best of the,...
(Date:11/20/2008)...Mass., Nov. 20 Radius Health ("Rad...onal $15 million to its second institutional finan...o $82.5 million and the total amount raised since ...sting institutional investors participated in the ...d including MPM Capital, The Wellcome Trust, Healt...
(Date:11/20/2008).... 20 PAREXEL Internation... biopharmaceutical services provider, today announ...provide regulatory consulting and clinical researc...ce, PAREXEL now has locations throughout five impo...which also include Argentina, Brazil, Chile, and M...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Mediterranean Diet May Ward Off Type 2 Diabetes 20660 1Mediterranean Diet May Ward Off Type 2 Diabetes 20660 2Mediterranean Diet May Ward Off Type 2 Diabetes 20660 3Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 20657 1Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 20657 2Technological Interventions Merge Into Health and Fitness 20654 1Technological Interventions Merge Into Health and Fitness 20654 2Technological Interventions Merge Into Health and Fitness 20654 3Brisk Walking Lowers Blood Pressure Increases Fitness in Obese 20651 1Brisk Walking Lowers Blood Pressure Increases Fitness in Obese 20651 2
...S WIRE)--Apr 26, 2007 - Northfield,Laboratories In...t,research organization has informed the Company t...l Phase III trauma trial with,PolyHeme(R), the Com...cell substitute, will not be complete until May., ...ories Inc. is a leader in developing an,oxygen-car...
... 0in 0pt; TEXT-ALIGN: left; tab-stops: 0in",align=...ops: list .5in; mso-list: l1 level1 lfo2">, <span ... MT,; mso-bidi-font-weight: bold">,Independent Jap...ng,Diovan to conventional therapy , , , ,<li st...so-list: l1 level1 lfo2">, <span style=,"FONT-SIZE...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 8Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 9Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 10Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 11Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 12
Take Performance to a Higher Level.
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC).
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic
... is used to seal the arterial puncture site. Duett...iotomy and the tissue tract with a flowable procoa...r and procoagulant - the Duett sealing device is d...he Duett is unique in its ability to quickly seal ...
Medicine Products: